Merz concludes enrolment in Phase III Xeomin trials for migraine
The studies enrolled around 1800 participants to test the drug's safety and efficacy in preventing both chronic and episodic migraine.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance